CERS

Cerus Corporation

A blood-safety company based in Concord, California, Cerus makes the INTERCEPT Blood System, a technology used by blood banks to zap donated platelets and plasma with UV light and a compound called amotosalen, neutralizing viruses, bacteria, and parasites before they reach patients. Founded in 1991 by hematologist Laurence Corash and chemist John Hearst, the company spun off its immunotherapy business in 2007 to focus on blood safety. Its product is aptly named: the system "intercepts" pathogens by cross-linking their DNA so they can't reproduce, rather than just screening for known ones.

CUSIP: 157085101HealthcareUS3 holders

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 5 years

Insider

Greenman William MarinerPresident and CEO, Director · 30 transactions

5.00M+229.1%

Granted 4.90M · Sold 1.46M

Corash Laurence MChief Scientific Officer · 18 transactions

2.34M+18%

as of Mar 2024

Granted 431.2K · Sold 74.1K

Jayaraman Vivek KChief Operating Officer · 29 transactions

1.66M+709.6%

Granted 1.94M · Sold 473.5K

Green Kevin DennisChief Financial Officer · 36 transactions

1.24M+1030.4%

Granted 1.76M · Sold 698.2K

Jensen ChrystalChief Legal Officer · 19 transactions

1.15M—

Granted 1.04M · Sold 410.2K

Benjamin Richard JChief Medical Officer · 40 transactions

777.4K+709.5%

Granted 1.38M · Sold 677.1K

Menard ChrystalChief Legal Officer · 15 transactions

509.5K+723.7%

as of Mar 2024

Granted 497.1K · Sold 95.8K

Moore CarolSVP Reg. & Quality · 20 transactions

501.0K+204.1%

as of Mar 2024

Granted 485.3K · Sold 191.3K

Witney FrankDirector · 6 transactions

340.1K+241.4%

Granted 220.5K · Bought 20.0K

Nachtsheim Jami KDirector · 7 transactions

268.4K+558.1%

Granted 225.6K · Bought 2.0K

Bjerkholt EricDirector · 10 transactions

261.7K+361.7%

Granted 220.5K · Bought 25.0K · Sold 40.5K

Lucena AnnDirector · 5 transactions

232.3K—

Granted 200.0K · Bought 7.5K

Swisher Daniel N JRDirector · 8 transactions

207.0K+121.8%

as of Jun 2025

Granted 173.0K · Bought 7.5K · Sold 12.5K

Moore Timothy L.Director · 5 transactions

205.1K+408.6%

as of Jun 2025

Granted 164.8K

Shan HuaDirector · 5 transactions

192.4K—

Granted 189.9K · Bought 2.5K

Schulze GailDirector · 7 transactions

163.4K+481.2%

as of Jun 2024

Granted 150.5K · Bought 9.8K · Sold 25.0K

Gregory Dean A.Director · 4 transactions

146.7K—

Granted 120.0K · Bought 26.7K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Greenman William MarinerPresident and CEO, Director · 30 transactions	+229.1%	5.00M	4.90M	—	1.46M
Corash Laurence MChief Scientific Officer · 18 transactions	+18%	2.34Mas of Mar 2024	431.2K	—	74.1K
Jayaraman Vivek KChief Operating Officer · 29 transactions	+709.6%	1.66M	1.94M	—	473.5K
Green Kevin DennisChief Financial Officer · 36 transactions	+1030.4%	1.24M	1.76M	—	698.2K
Jensen ChrystalChief Legal Officer · 19 transactions	—	1.15M	1.04M	—	410.2K
Benjamin Richard JChief Medical Officer · 40 transactions	+709.5%	777.4K	1.38M	—	677.1K
Menard ChrystalChief Legal Officer · 15 transactions	+723.7%	509.5Kas of Mar 2024	497.1K	—	95.8K
Moore CarolSVP Reg. & Quality · 20 transactions	+204.1%	501.0Kas of Mar 2024	485.3K	—	191.3K
Witney FrankDirector · 6 transactions	+241.4%	340.1K	220.5K	20.0K	—
Nachtsheim Jami KDirector · 7 transactions	+558.1%	268.4K	225.6K	2.0K	—
Bjerkholt EricDirector · 10 transactions	+361.7%	261.7K	220.5K	25.0K	40.5K
Lucena AnnDirector · 5 transactions	—	232.3K	200.0K	7.5K	—
Swisher Daniel N JRDirector · 8 transactions	+121.8%	207.0Kas of Jun 2025	173.0K	7.5K	12.5K
Moore Timothy L.Director · 5 transactions	+408.6%	205.1Kas of Jun 2025	164.8K	—	—
Shan HuaDirector · 5 transactions	—	192.4K	189.9K	2.5K	—
Schulze GailDirector · 7 transactions	+481.2%	163.4Kas of Jun 2024	150.5K	9.8K	25.0K
Gregory Dean A.Director · 4 transactions	—	146.7K	120.0K	26.7K	—

Select a row to see that insider’s individual transactions.